Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
Clinical trial NCT05574881 · UNKNOWN
Trial details
- NCT number
- NCT05574881
- Sponsor
- Fudan University
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-01
- Primary completion
- 2025-01-01
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.